Concr — which was described as a “deeptech company dedicated to enabling precision medicine and improving drug development using predictive analytics and artificial intelligence [AI]” — announced its partnership with CariGenetics. A spokesperson said, “Through this collaboration, Concr and CariGenetics will expand use of vital genetic and molecular data on Triple Negative Breast Cancer [TNBC] […]